SINOVAC BIOTECH LTD(SVA)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Limited institutional coverage
Quality rankings require at least 50 unique 13-F institutional holders to ensure peer comparisons are meaningful. Only 29 institutional filers currently hold this stock.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
SVA Stock Analysis & AI Quality Score
AI stock analysis and institutional research for SINOVAC BIOTECH LTD (SVA), a Healthcare sector company. SVA is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least 50 unique 13-f institutional holders to ensure peer comparisons are meaningful. only 29 institutional filers currently hold this stock. Based on the latest XBRL financial filings (FY 2025), SINOVAC BIOTECH LTD reports quarterly revenue of $386.0M, net income of $-198.8M, free cash flow of $-561.1M. Top institutional holders of SVA by reported 13-F value include ORBIMED ADVISORS, Vivo Capital,, SUSQUEHANNA INTERNATIONAL GROUP, LLP, based on the most recent SEC filings. SVA trades on the Nasdaq exchange and files with the SEC under CIK 1084201. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SVA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for SINOVAC BIOTECH LTD directly from SEC EDGAR.
Revenue
FY 2025
$386.0M
Net Income
FY 2025
$-198.8M
Free Cash Flow
FY 2025
$-561.1M
D/E Ratio
FY 2025
0.11
AI Insight: SVA Financial Trends
Equity base collapsed 46% year-over-year while debt nearly doubled, signaling severe balance-sheet deterioration.
• Total debt surged from $376M in Q4 2024 to $495M in Q4 2025, a 32% increase.
• Shareholder equity plummeted from $8.3B in Q4 2024 to $4.4B in Q4 2025, a 46% decline.
• Debt-to-equity ratio deteriorated sharply to 11.2% in Q4 2025 from 4.6% in Q4 2024.
⚠ Equity has contracted nearly 53% from peak of $9.3B in Q4 2021; underlying cause of erosion unclear from balance-sheet data alone.
⚠ Missing revenue, net income, and operating cash flow data prevents assessment of operational health driving balance-sheet changes.
AI Insight: SVA Ratio Trends
Leverage has doubled to 0.11 D/E by end-2025, the highest level in seven years, signaling a shift in capital structure.
• Debt-to-equity ratio rose from 0.05 in Q4 2024 to 0.11 in Q4 2025, matching TTM 0.11.
• D/E levels remain well below 2018–2020 peaks (0.03–0.05 range), indicating balance sheet still conservative historically.
⚠ D/E doubled in one year; monitor whether debt accumulation reflects strategic investment or operational stress.
Get alerted when SVA's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for SINOVAC BIOTECH LTD including:
Top Institutional Holders of SVA
ORBIMED ADVISORS LLC
$184.5M2,718,735 shVivo Capital, LLC
$38.2M5,903,000 shSUSQUEHANNA INTERNATIONAL GROUP, LLP
$106.3K16,430 shMORGAN STANLEY
$59.2K9,144 shWELLS FARGO & COMPANY/MN
$31.1K4,811 shUBS Group AG
$14.4K2,229 shNeumann Advisory Hong Kong Ltd
$2.0K315,586 shHorizon Investments, LLC
$673.00104 shHARBOUR INVESTMENTS, INC.
$542.0083 shAtlantic Edge Private Wealth Management, LLC
$0.001,000 sh
| Fund | Value | Shares |
|---|---|---|
| ORBIMED ADVISORS LLC | $184.5M | 2,718,735 |
| Vivo Capital, LLC | $38.2M | 5,903,000 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $106.3K | 16,430 |
| MORGAN STANLEY | $59.2K | 9,144 |
| WELLS FARGO & COMPANY/MN | $31.1K | 4,811 |
| UBS Group AG | $14.4K | 2,229 |
| Neumann Advisory Hong Kong Ltd | $2.0K | 315,586 |
| Horizon Investments, LLC | $673.00 | 104 |
| HARBOUR INVESTMENTS, INC. | $542.00 | 83 |
| Atlantic Edge Private Wealth Management, LLC | $0.00 | 1,000 |
More Healthcare Companies
View all Healthcare →Put SVA on your watchlist
Track score changes the day SINOVAC BIOTECH LTD files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is SVA a good stock to buy?
13F Pro's AI-powered analysis of SINOVAC BIOTECH LTD (SVA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SVA are available on the SVA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own SVA?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SVA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of SINOVAC BIOTECH LTD's investment landscape.